Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris
- Registration Number
- NCT04163263
- Lead Sponsor
- Boston Pharmaceuticals
- Brief Summary
This study is being conducted to characterize the safety and tolerability of BOS-356 in adult participants with moderate to severe acne vulgaris following 14 days or 28 days of repeated topical application
- Detailed Description
In Cohorts 1-3, participants will be randomized to receive twice daily (BID) topical applications of BOS-356 gel or vehicle gel to the face during a 14-day treatment period. Doses will be escalated in successive cohorts with BOS-356 gel 0.1%, 0.4%, and 0.7%.
In Cohort 4, participants will be randomized to receive BID topical applications of BOS-356 gel or vehicle gel to the face, upper chest, upper back, shoulders, and posterior neck during a 28-day treatment period. The dose of BOS-356 to be used in this cohort will be determined based on safety and tolerability data from Cohorts 1-3.
In Cohort 5, participants will complete a 7-day run-in period to receive BID topical applications of vehicle gel to the face. Participants will be randomized to receive BID topical applications of BOS-356 gel or vehicle gel to the face during a 28-day treatment period. The dose of BOS-356 to be used in this cohort will be the same as the dose used in Cohort 4. Cohorts 4 and 5 may proceed in parallel.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 66
For Cohorts 1-5:
- Male or female participants aged 18 to 45 years, inclusive, at the time of consent
- Participant has moderate to severe non-nodular facial acne vulgaris.
- Participant's treatment with hormonal therapy (including, but not limited to, topical application, oral administration, implant, intrauterine device [IUD]) has been on a stable dose and frequency for at least 12 weeks before Day 1, and participant agrees to maintain current dose and frequency throughout the study.
- Female participants of childbearing potential and male participants and their female partners who are of childbearing potential must agree to use a highly effective contraceptive method
- Participant is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.
Additional Inclusion Criteria for Cohort 4 only:
• Participant has additional acne lesions on the upper back with at least 5 inflammatory lesions and additional acne lesions on the posterior neck, shoulders, and/or upper chest.
For Cohorts 1-5:
- Participant is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
- Participant has acne fulminans, conglobata, nodulocystic acne, or secondary acne.
- Participant has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
- Excessive facial hair that would interfere with diagnosis or assessment of acne vulgaris
- Participant is known to have immune deficiency or is immunocompromised.
- Participant has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Participants with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix may be candidates for the study.
- Participant had a major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study.
- Participant has positive results for hepatitis B surface antigens (HBsAg), antibodies to hepatitis B core antigens (anti-HBc), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
- Participant has used on the treated areas an over-the-counter (OTC) topical medication for the treatment of acne vulgaris, including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, salicylic acid, α-hydroxy/glycolic, or antibacterial/antiseptic soap or wash within 2 weeks prior to Day 1.
- Participant has used prescription topical retinoid (e.g., tretinoin, tazarotene, adapalene), dapsone or antimicrobials (e.g., clindamycin, erythromycin), or other prescription topical medications for the treatment of acne vulgaris within 4 weeks prior to Day 1. Topical antibiotics may be used to treat non-acne skin lesions outside of the treated area.
- Participant has used systemic antibiotics or other systemic anti-acne drugs not mentioned in other exclusion criteria within 4 weeks prior to Day 1.
- Participant has used oral or injectable corticosteroids within 4 weeks prior to Day 1 or require them during the study. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.
- Participant had a facial procedure (including, but not limited to, chemical peel, laser, microdermabrasion) within 8 weeks prior to Day 1 and during the study.
- Participant has received photodynamic therapy or phototherapy within 12 weeks of Day 1.
- Participant has used androgen receptor blockers (such as spironolactone or flutamide) within 12 weeks prior to Day 1.
- Participant has used drospirenone, chlormadinone acetate, or cyproterone acetate within 26 weeks prior to Day 1.
- Participant has used oral retinoid (e.g., isotretinoin) within 52 weeks prior to Day 1 or vitamin A supplements >10,000 Units per day (U/d) within 26 weeks prior to Day 1.
- Participant is currently receiving a nonbiological investigational product or device or has received one within 4 weeks or five half-lives (whichever is longer) prior to Day 1.
- Participant has received blue light, laser, intense pulsed light or other light therapy on the face within 4 weeks prior to Day 1.
- Participants who have given > 50 milliliters (mL) of blood or plasma within 30 days of Screening or > 499 mL of blood or plasma within 56 days of Screening (during a clinical trial or at a blood bank donation).
- Participant has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1, or has a positive drug screen and/or positive alcohol test result at the Screening visit or at Day 1 (excluding cannabinoids).
- Participant has had excessive sun exposure or has used tanning booths within 4 weeks prior to Day 1 or is not willing to minimize natural and artificial sunlight exposure during the study. Use of sunscreen products (except on treated areas) and protective apparel are recommended when sun exposure cannot be avoided.
For Cohorts 1-3 only:
• Participant has a Fitzpatrick's Skin Phototype ≥5.
For Cohort 4 only, due to biopsy collection:
- Participant has a history of an allergic reaction or significant sensitivity to lidocaine or other local anesthetics.
- Participant has a history of hypertrophic scarring or keloid.
- Participant has taken anticoagulant medication, such as heparin, low molecular weight (LMW)-heparin, warfarin, antiplatelets, within 2 weeks prior to Day 1, or has a contraindication to skin biopsies. Nonsteroidal anti-inflammatory drugs (NSAIDs) will not be considered antiplatelets and will be allowed.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Cohorts 1-3: Vehicle Vehicle Twice daily application of vehicle gel Cohort 4: Vehicle Vehicle Twice daily application of vehicle gel Cohorts 1-3: BOS-356 BOS-356 Twice daily application of BOS-356 0.1%, 0.4%, and 0.7% gel in Cohorts 1, 2, and 3, respectively Cohort 5: Vehicle Vehicle Twice daily application of vehicle gel Cohort 5: BOS-356 BOS-356 Twice daily application of BOS-356 gel at a dose determined based on safety and tolerability data from Cohorts 1-3 Cohort 4: BOS-356 BOS-356 Twice daily application of BOS-356 gel at a dose determined based on safety and tolerability data from Cohorts 1-3
- Primary Outcome Measures
Name Time Method Cohort 5: Number of participants with any AE and any SAE up to Day 42 Cohort 4: Number of participants with a mild, moderate, and severe score in LTAs up to Day 35 Cohorts 1-3: Number of participants with any clinically significant change from baseline in vital sign values up to Day 21 for each cohort Cohort 5: Number of participants with a mild, moderate, and severe score in LTAs up to Day 42 Cohorts 4 and 5: Number of participants with any clinically significant change from baseline in clinical laboratory parameter values up to Day 35 for each cohort Cohorts 1-3: Number of participants with any adverse event (AE) and any serious adverse event (SAE) up to Day 21 for each cohort Cohorts 1-3: Number of participants with any clinically significant change from baseline in electrocardiogram (ECG) findings up to Day 14 for each cohort Cohorts 1-3: Number of participants with a mild, moderate, and severe score in local tolerability assessments (LTAs) up to Day 21 for each cohort Cohorts 1-3: Number of participants with any clinically significant change from baseline in clinical laboratory parameter values up to Day 21 for each cohort Cohort 4: Number of participants with any AE and any SAE up to Day 35 Cohorts 4 and 5: Number of participants with any clinically significant change from baseline in vital sign values up to Day 35 for each cohort Cohorts 4 and 5: Number of participants with any clinically significant change from baseline in ECG findings up to Day 35 for each cohort
- Secondary Outcome Measures
Name Time Method Cohorts 1-3: Plasma concentration of BOS-356 up to Day 21 for each cohort Days 1 and 14: pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours post morning (AM) dose. Days 2 and 7: pre-dose; 1 and 2 hours post AM dose. Day 15: 24 hours (± 2 hours) post last dose. Follow-Up visit (Day 21) (or end-of-treatment, if applicable): at time of visit
Cohort 4: Plasma concentration of BOS-356 up to Day 35 Days 1 and 14: pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours post AM dose. Days 2, 7, and 15: pre-dose; 1 and 2 hours post AM dose. Day 28: pre-dose; 1, 2, 4, 6, and 8 hours post AM dose. Follow-Up visit (Day 35) (or end-of-treatment, if applicable): at time of visit
Cohort 5: Plasma concentration of BOS-356 up to Day 35 Day 1: pre-dose. Days 7, 14, and 28 pre-dose (approximately 12 hours \[± 4 hours\] from the previous dose. Follow-Up visit (Day 35): at time of visit
Trial Locations
- Locations (7)
Center for Dermatology Clinical Research
🇺🇸Fremont, California, United States
International Clinical Research
🇺🇸Sanford, Florida, United States
Innovaderm Research, Inc.
🇨🇦Montreal, Canada
Dermatology Consulting Services
🇺🇸High Point, North Carolina, United States
J&S Studies, Inc.
🇺🇸College Station, Texas, United States
DermResearch, Inc.
🇺🇸Austin, Texas, United States
Progressive Clinical Research
🇺🇸San Antonio, Texas, United States